The probe into insider trading continues with authorities looking at a number of funds, including SAC Capital, a source tells CNBC.» Read More
Elan, Merck, Amazon, Qualcomm and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Shares of Neurochem today are trading at a new low after the Canadian biotech announced its developmental drug for Alzheimer's didn't work well enough. It is the latest evidence that cracking the code of this complex disease is extremely challenging. We recently did a story on the drug called Alzhemed, the potential AD-drug market and other companies working on treatments/cures at a dementia conference in Washington, DC.
As the push for universal health care in the U.S. heats up on Capitol Hill, market experts say generic drug stocks and pharmaceutical distributors should perform well, while the hit to big pharma may not be as bad as some anticipate.
Yahoo!, Mastercard, JC Penney and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Hey everyone, here's a look at the contest stock report. The biggest change appears to be GIGM which appears on the actives list for the first time--as part of the Chinese online gaming play betting on strong earnings before the bell Tuesday. Here you go:
Stocks ended mixed as the S&P 500 failed to hold above its previous record, despite another busy day of mergers and acquisitions activity. "Everyone knew that the S&P was going to reach its old record but clearly there is resistance there," said Stephen Porpora, managing floor broker at William O'Neil.
Shares of drug developers Wyeth and Elan jumped Monday after the companies said they plan on asking for approval to move their Alzheimer's treatment candidate bapineuzumab into late-stage studies.
M&A news and drug trial updates provided some of the catalysts behind the most actively traded stocks on Monday.
Good morning all. Parker Robinson and James Kraber remain in the top two positions, with James holding the 2nd and 4th positions, and remember Deborah Taft? She made a strong move back into third place. Parker's portfolio value stands at $2,796,103.27, up $3,000 from Monday on bonus bucks.
good morning. Deborah Taft and Chad Mazeika continue to hold the top two spots, but Chad continues to gain on Deborah. Deborah's portfolio gained $3,000 in bonus bucks to $2,582,876.30. Her strategy of all cash appears to be working, but her lead is narrowing with only about $224,000 separating her and Chad--which is down from $245,000 on Monday.
Actor Stephen Collins continues to make solid gains each day--and he's very consistent in adding $3,000 a day in Bonus Bucks (so that's why we put in his picture). His strategy is paying off as he builds his lead in "Trading With The Stars." Actor Ernie Hudson is making some buys and sells as is Hall of Famer Johnny Bench--who's still in 9th place, but at least he's staying out of the cellar..
Good morning all. Deborah Taft continues to hold the top position, but she is losing ground. And there's a new number two; Jason Kaplan. Jason gains 2nd place on his Worthington Industries trade forcing Chad Mazeika into 3rd place with only small gains on Mariner Energy and Sonus.
Good morning. Deborah Taft and Chad Mazeika maintain their stranglehold on the two top positions of the Leaderboard. Deborah continues in the lead with a portfolio value of $2,585,726.30 up $3k from Tuesday's total of $2,582,726.3 on bonus bucks alone. After Deborah's trade on CVTX she was all in cash before executing two buys Wednesday...
Good morning. Deborah Taft continues in the lead with a portfolio value of $2,582,726.3, up $366,000 Tuesday, from Monday's value of $2,216,726.30. Deborah's gamble on the ever-active CV Therapeutics paid off and secured her lead position. She went all in on Monday with a buy of 300,000 shares of CVTX at $6.75, and it looks like she caught a bottom...
Good morning. Here are the latest names and numbers from Monday's action. Deborah Taft continues in the lead with a portfolio value of $2,216,726.30. Her biggest portfolio gains continue to be in the ever popular Fremont General which she sold out of completely on 3/21. She made $23,062.62 or 1.05% on buying and selling 164,733 shares of Elan Pharma.
Good morning. Deborah Taft stays in the top position with a portfolio value of $2,187,663.68 for a gain of $2,000.00 or 0.09% from Thursday's action. Deborah was all in cash and received $2,000 in bonus bucks and has put the majority of her holdings into Elan Corp. plc (ELN) as of 3/22. (those bonus bucks from the trivia questions do add up!!)
Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.
The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.